Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | NEJM
Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results r…